|
| 36317715 | A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer. | J Urol | 2023 |
| 37385724 | Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas. | J Immunother Cancer | 2023 |
| 36959716 | Outpatient administration of paclitaxel, ifosfamide, and cisplatin (TIP) for germ cell tumor. | J Oncol Pharm Pract | 2023 |
| 36787089 | First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors. | Target Oncol | 2023 |
| 36750016 | Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. | J Clin Oncol | 2023 |
| 35176457 | FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. | Ann Oncol | 2022 |
| 35472327 | Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series. | Urology | 2022 |
| 33941878 | Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. | Br J Cancer | 2021 |
| 33630025 | Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. | JAMA Oncol | 2021 |
| 33617303 | TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. | J Clin Oncol | 2021 |
| 35008431 | Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). | Int J Mol Sci | 2021 |
| 31527168 | Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. | Clin Cancer Res | 2020 |
| 32031899 | EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. | J Clin Oncol | 2020 |
| 32913286 | Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. | Br J Cancer | 2020 |
| 32299729 | Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. | Clin Genitourin Cancer | 2020 |
| 30591982 | A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors. | Invest New Drugs | 2019 |
| 31805523 | Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2019 |
| 31853198 | First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. | Cancer Manag Res | 2019 |
| 30132271 | A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. | Invest New Drugs | 2019 |
| 30229512 | A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. | Invest New Drugs | 2019 |
| 31023520 | Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience. | Clin Genitourin Cancer | 2019 |
| 30624766 | A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma. | Cancer | 2019 |
| 29236570 | Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. | J Clin Oncol | 2018 |
| 30192374 | Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de-implementation. | Cancer | 2018 |
| 30042870 | Multimodal imaging provides insight into targeted therapy response in metastatic prostate cancer to the bone. | Am J Nucl Med Mol Imaging | 2018 |
| 30265610 | Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). | J Clin Oncol | 2018 |
| 30693182 | Detection of CTC Clusters and a Dedifferentiated RNA-Expression Survival Signature in Prostate Cancer. | Adv Sci (Weinh) | 2018 |
| 29570421 | Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. | J Clin Oncol | 2018 |
| 29453313 | Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. | Mol Cancer Res | 2018 |
| 29261439 | Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. | J Clin Oncol | 2018 |
| 28783718 | Integrative clinical genomics of metastatic cancer. | Nature | 2017 |
| 28314841 | Academic Cancer Center Phase I Program Development. | Oncologist | 2017 |
| 28242752 | Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers. | Cancer Discov | 2017 |
| 29059635 | Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. | Eur J Cancer | 2017 |
| 28954784 | A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2017 |
| 29163793 | Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. | Oncotarget | 2017 |
| 28755607 | A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. | Eur J Cancer | 2017 |
| 26984445 | Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. | Oncologist | 2016 |
| 26576779 | First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. | Cancer Chemother Pharmacol | 2016 |
| 27379498 | Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors. | Cancer Chemother Pharmacol | 2016 |
| 27312733 | Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors. | Cancer Chemother Pharmacol | 2016 |
| 26806347 | Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. | Neoplasia | 2016 |
| 24631409 | Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. | Eur Urol | 2015 |
| 28799570 | A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. | Adv Radiat Oncol | 2015 |
| 28843286 | Integrative Clinical Genomics of Advanced Prostate Cancer. | Cell | 2015 |
| 26281907 | A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. | Cancer Chemother Pharmacol | 2015 |
| 25897158 | Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. | J Clin Oncol | 2015 |
| 26000489 | Integrative clinical genomics of advanced prostate cancer. | Cell | 2015 |
| 25716544 | Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. | Cancer Chemother Pharmacol | 2015 |
| 25777468 | Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. | Invest New Drugs | 2015 |